We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · December 16, 2020

Effect of Capecitabine Maintenance Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival in Early-Stage Triple-Negative Breast Cancer

JAMA: The Journal of the American Medical Association

 

Additional Info

JAMA: The Journal of the American Medical Association
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial
JAMA 2020 Dec 10;[EPub Ahead of Print], X Wang, SS Wang, H Huang, L Cai, L Zhao, RJ Peng, Y Lin, J Tang, J Zeng, LH Zhang, YL Ke, XM Wang, XM Liu, QJ Chen, AQ Zhang, F Xu, XW Bi, JJ Huang, JB Li, DM Pang, C Xue, YX Shi, ZY He, HX Lin, X An, W Xia, Y Cao, Y Guo, YH Su, X Hua, XY Wang, RX Hong, KK Jiang, CG Song, ZZ Huang, W Shi, YY Zhong, ZY Yuan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading